Expecting soon in unchartered territories📊 Quarter: Q2 FY2025 (ended June 30, 2025)
💰 Revenue: ₹220.90 Cr (↑ 28.2% YoY; ↑ 27.9% QoQ)
💸 PAT: ₹60.70 Cr (↑ 109.3% YoY)
📌 O‑P Margin: ~31.8% vs 36.9% in Q2 FY2024
🧾 EPS (Basic/Diluted): ₹26.36 (vs ₹12.58 in Q2 FY2024)
Strong volume-led growth across key brands. Sales rebound sharply after demerger and previous product recalls.
PAT doubling YoY reflects robust operational leverage and cost efficiencies, despite some margin contraction.
Sanofi Consumer Health posted a very strong Q2 with double-digit sales and profit growth. Despite margin compression, the EPS surge and successful brand relaunches offer bullish medium-term potential — making this a Buy on dips or breakout opportunity.
